FOXP1蛋白在弥漫性大B细胞淋巴瘤中的表达及其与预后的关系

Expression of FOXP1 in diffuse large B cell lymphoma and its relationship with prognosis

目的:观察FOXP1蛋白在不同亚型的弥漫性大B细胞淋巴瘤(diffuse large B cell lymphoma,DLBCL)组织中的表达,并探讨其与预后的关系。方法:回顾性分析2004年1月—2007年12月广西医科大学附属肿瘤医院诊断明确、病例资料齐全的DLBCL患者的石蜡标本共86例,应用免疫组织化学法检测肿瘤组织中FOXP1蛋白表达情况,采用χ2检验比较FOXP1不同表达组与化疗后完全缓解率之间的关系。结果:86例DLBCL标本中,生发中心型47例,其中FOXP1阳性者10例(21.28%);非生发中心型39例,其中FOXP1阳性者31例(79.49%);2组患者的FOXP1表达率差异有统计学意义(P<0.05)。FOXP1阳性的41例患者中化疗后完全缓解(complete response,CR)者10例(24.39%),FOXP1阴性的45例患者中化疗后CR者29例(64.44%),2者CR率的差异有统计学意义(P<0.05)。FOXP1表达与患者的性别、年龄、临床分期、乳酸脱氢酶水平、PS评分、淋巴结外侵犯情况、B症状及有无巨大包块均无关。结论:FOXP1蛋白主要在非生发中心型DLBCL组织中表达,阳性表达的患者CR率低,可以利用FOXP1蛋白表达水平预测DLBCL的预后。

Objective：To analyze the Forkhead box protein P1 （FOXP1） expression in diffuse large B cell lymphoma（DLBCL） and explore its relationship with prognosis. Methods：The clinical data from 86 DLBCL patients who were treated in Guangxi Cancer Hospital from January 2004 to December 2007 were retrospectively analyzed. FOXP1 expression was detected with immunohistochemis- try. The relationship between FOXP1 expression and the rate of complete remission （CR） was evaluated by Chi-square test. Results： There were 47 cases of germinal center type （GC） out of 86 DLBCL specimens. Ten of the 47 cases had positive FOXP1 expression （21.28%）. For the 39 cases of non-germinal center type （ non-GC）, 31 cases were positive for FOXP1 （79.49%）. The FOXP1 posi- tivity was significantly different between GC and non-GC （P 〈0.05）. CR was observed in 24.39% （10/41） FOXPl-positive patients and 64.44% （29/45） FOXPl-negative patients. The difference was significant （P 〈 0.05）. The expression of FOXP1 was not related with gender, age, clinical stage, LDH level, PS score, extranodal invasion, B symptom and bulky disease. Conclusion： FOXP1 is pre- dominantly expressed in non-GC DLBCL tissues, and FOXPl-positive patients have low CR rate. FOXP1 expression could be used to predict the therapeutic efficacy and prognosis of DLBCL.